Skip to main content
Top
Published in: Journal of Gastrointestinal Surgery 1/2007

01-01-2007

Predicting Unresectability in Pancreatic Cancer Patients: The Additive Effects of CT and Endoscopic Ultrasound

Authors: Susannah Yovino, Peter Darwin, Barry Daly, Michael Garofalo, Robert Moesinger

Published in: Journal of Gastrointestinal Surgery | Issue 1/2007

Login to get access

Abstract

Background

A standardized method for predicting unresectability in pancreatic cancer has not been defined. We propose a system using CT and endoscopic ultrasound (EUS) to assess patients for unresectable pancreatic cancers.

Methods

Radiologic and surgical data from 101 patients who underwent exploration/resection for pancreatic cancer were reviewed. Chi-squares were used to identify five factors significantly correlated with unresectability, which were incorporated into a scoring system (one point for each factor).

Results

The resectability rates were 84, 56, and 10% for patients with scores of 0, 1, and 2, respectively. All four patients with three risk factors for unresectability had unresectable tumors. The most accurate results were achieved in patients evaluated with both CT and EUS.

Discussion

This scoring system stratifies pancreatic cancer patients into three groups: (1) patients with a score of zero (likely to undergo successful resection), (2) patients with a score of one (likely to benefit from laparoscopic staging prior to attempting resection), and (3) patients with a score of two or higher (low probability of successful resection, who may be better served by neoadjuvant therapy).
Literature
1.
2.
go back to reference Yeo CJ, Cameron JL, Lillemoe KD, et al. Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients. Ann Surg 1995;221(6):721–731.PubMedCrossRef Yeo CJ, Cameron JL, Lillemoe KD, et al. Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients. Ann Surg 1995;221(6):721–731.PubMedCrossRef
3.
go back to reference Moertel CG, Frytak S, Hahn RG, et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: the Gastrointestinal Tumor Study Group. Cancer 1981;48(8):1705–1710.PubMedCrossRef Moertel CG, Frytak S, Hahn RG, et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: the Gastrointestinal Tumor Study Group. Cancer 1981;48(8):1705–1710.PubMedCrossRef
4.
go back to reference Gastrointestinal Tumor Study Group. Radiation therapy combined with adriamycin or 5-fluorouracil for the treatment of locally unresectable pancreatic carcinoma. Cancer 1985;56(11):2563–2568.CrossRef Gastrointestinal Tumor Study Group. Radiation therapy combined with adriamycin or 5-fluorouracil for the treatment of locally unresectable pancreatic carcinoma. Cancer 1985;56(11):2563–2568.CrossRef
5.
go back to reference Klaassen DJ, MacIntyre JM, Catton GE, et al. Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil—an Eastern Cooperative Oncology Group study. J Clin Oncol 1985;3(3):373–378.PubMed Klaassen DJ, MacIntyre JM, Catton GE, et al. Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil—an Eastern Cooperative Oncology Group study. J Clin Oncol 1985;3(3):373–378.PubMed
6.
go back to reference Gastrointestinal Tumor Study Group. Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst 1988;80(10):751–755.CrossRef Gastrointestinal Tumor Study Group. Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst 1988;80(10):751–755.CrossRef
7.
go back to reference Mittal A, Windsor J, Casey P, et al. Matched study of three methods of palliation for malignant pyloroduodenal obstruction. Br J Surg 2004 Feb;91(2):205–209.PubMedCrossRef Mittal A, Windsor J, Casey P, et al. Matched study of three methods of palliation for malignant pyloroduodenal obstruction. Br J Surg 2004 Feb;91(2):205–209.PubMedCrossRef
8.
go back to reference Maetani I, Tada T, Ukita T, et al. Comparison of duodenal stent placement with surgical gastrojejunostomy for palliation in patients with duodenal obstructions caused by pancreaticobiliary malignancies. Endoscopy 2004;36(1):73–78.PubMedCrossRef Maetani I, Tada T, Ukita T, et al. Comparison of duodenal stent placement with surgical gastrojejunostomy for palliation in patients with duodenal obstructions caused by pancreaticobiliary malignancies. Endoscopy 2004;36(1):73–78.PubMedCrossRef
9.
go back to reference Levy M, Wiersema M. EUS-guided celiac plexus neurolysis and celiac plexus block. Gastrointest Endosc 2003;57(7):923–930.PubMedCrossRef Levy M, Wiersema M. EUS-guided celiac plexus neurolysis and celiac plexus block. Gastrointest Endosc 2003;57(7):923–930.PubMedCrossRef
10.
go back to reference Espat N, Brennan MF, Conlon KC. Patients with laparoscopically staged unresectable pancreatic adenocarcinoma do not require subsequent surgical biliary or gastric bypass. J Am Coll Surg 1999;188(6):649–655.PubMedCrossRef Espat N, Brennan MF, Conlon KC. Patients with laparoscopically staged unresectable pancreatic adenocarcinoma do not require subsequent surgical biliary or gastric bypass. J Am Coll Surg 1999;188(6):649–655.PubMedCrossRef
11.
go back to reference Dewitt J, Devereaux B, Chriswell M. et al. Comparison of endoscopic ultrasonography and multidetector computed tomography for diagnosis and staging of pancreatic cancer. Ann Intern Med 2004;141(10):753–763.PubMed Dewitt J, Devereaux B, Chriswell M. et al. Comparison of endoscopic ultrasonography and multidetector computed tomography for diagnosis and staging of pancreatic cancer. Ann Intern Med 2004;141(10):753–763.PubMed
12.
go back to reference Ahmad N, Lewis J, Ginsberg G. EUS in preoperative staging of pancreatic cancer. Gastrointest Endosc 2000;52(4):463–468.PubMedCrossRef Ahmad N, Lewis J, Ginsberg G. EUS in preoperative staging of pancreatic cancer. Gastrointest Endosc 2000;52(4):463–468.PubMedCrossRef
13.
go back to reference Valls C, Andia E, Sanchez A. Dual-phase helical CT of pancreatic adenocarcinoma: assessment of resectability before surgery. AJR Am J Roentgenol 2002 Apr;178(4):821–826.PubMed Valls C, Andia E, Sanchez A. Dual-phase helical CT of pancreatic adenocarcinoma: assessment of resectability before surgery. AJR Am J Roentgenol 2002 Apr;178(4):821–826.PubMed
14.
go back to reference Fuhrman GM, Charnsangavej C, Abbruzzese JL. Thin-section contrast-enhanced computed tomography accurately predicts the resectability of malignant pancreatic neoplasms. Am J Surg 1994;167(1):104–111; discussion 111–113.PubMedCrossRef Fuhrman GM, Charnsangavej C, Abbruzzese JL. Thin-section contrast-enhanced computed tomography accurately predicts the resectability of malignant pancreatic neoplasms. Am J Surg 1994;167(1):104–111; discussion 111–113.PubMedCrossRef
15.
go back to reference Schlieman MG, Ho HS, Bold RJ. Utility of tumor markers in predicting resectability of pancreatic cancer. Arch Surg 2003;138(9):951–955.PubMedCrossRef Schlieman MG, Ho HS, Bold RJ. Utility of tumor markers in predicting resectability of pancreatic cancer. Arch Surg 2003;138(9):951–955.PubMedCrossRef
16.
go back to reference Merchant NB, Conlon KC, Saigo P, et al. Positive peritoneal cytology predicts unresectability of pancreatic adenocarcinoma. J Am Coll Surg 1999;188(4):421–426.PubMedCrossRef Merchant NB, Conlon KC, Saigo P, et al. Positive peritoneal cytology predicts unresectability of pancreatic adenocarcinoma. J Am Coll Surg 1999;188(4):421–426.PubMedCrossRef
17.
go back to reference Kelsen DP, Portenoy R, Thaler H, et al. Pain as a predictor of outcome in patients with operable pancreatic carcinoma. Surgery 1997 Jul;122(1):53–59.PubMedCrossRef Kelsen DP, Portenoy R, Thaler H, et al. Pain as a predictor of outcome in patients with operable pancreatic carcinoma. Surgery 1997 Jul;122(1):53–59.PubMedCrossRef
Metadata
Title
Predicting Unresectability in Pancreatic Cancer Patients: The Additive Effects of CT and Endoscopic Ultrasound
Authors
Susannah Yovino
Peter Darwin
Barry Daly
Michael Garofalo
Robert Moesinger
Publication date
01-01-2007
Publisher
Springer-Verlag
Published in
Journal of Gastrointestinal Surgery / Issue 1/2007
Print ISSN: 1091-255X
Electronic ISSN: 1873-4626
DOI
https://doi.org/10.1007/s11605-007-0110-6

Other articles of this Issue 1/2007

Journal of Gastrointestinal Surgery 1/2007 Go to the issue